Tavia Acquisition (TAVI) institutional holders disclose ~5–6% stakes in Schedule 13G
Rhea-AI Filing Summary
Tavia Acquisition Corp. reports institutional holdings disclosed on a Schedule 13G. Westchester Capital Management, LLC beneficially owns 680,000 shares (5.91%); Virtus Investment Advisers, LLC beneficially owns 646,288 shares (5.62%); The Merger Fund beneficially owns 625,033 shares (5.44%). These percentages are calculated based on 11,500,000 shares outstanding as of March 16, 2026, per the filing. The filing shows allocation of voting and dispositive powers: Westchester reports 33,712 shares of sole voting and dispositive power and shared voting/dispositive power over 646,288 shares; Virtus and The Merger Fund report only shared voting and dispositive power over their respective holdings. The statement is filed jointly by the three reporting entities and is signed by their compliance officers.
Positive
- None.
Negative
- None.
Insights
Joint disclosure shows concentrated institutional holdings near 5–6% each.
The filing lists three related reporting persons with overlapping positions: Westchester, Virtus, and The Merger Fund. Each holds between 625,033 and 680,000 shares, with shared voting/dispositive arrangements reflecting adviser/sub-adviser relationships.
Key dependencies include the 11,500,000 shares outstanding as of March 16, 2026 anchor and the reporting persons' allocation of sole versus shared powers; subsequent filings would show any material changes to these percentages.
Shared control among adviser entities suggests coordinated reporting, not independent block holders.
The disclosure explains that Virtus is adviser to the funds and Westchester is sub-adviser, which accounts for overlapping shared voting and dispositive power entries. The Merger Fund’s holdings are included within the adviser aggregates.
Investors reviewing governance should note the joint filing structure and that voting power is largely shared, as specified in the ownership table.
Key Figures
Key Terms
beneficially owned regulatory
CUSIP market
Schedule 13G regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.